Lilly beats Novo in bellwether head-to-head weight loss study - Endpoints News
- Lilly beats Novo in bellwether head-to-head weight loss study Endpoints News
- Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial CNBC
- Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Investors | Eli Lilly and Company
- Eli Lilly’s stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial MarketWatch